Axa boosted its position in Aduro BioTech Inc (NASDAQ:ADRO) by 85.9% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 42,756 shares of the biotechnology company’s stock after acquiring an additional 19,756 shares during the period. Axa owned about 0.05% of Aduro BioTech worth $314,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Capital Fund Management S.A. purchased a new stake in shares of Aduro BioTech during the 2nd quarter valued at $130,000. MetLife Investment Advisors LLC grew its stake in shares of Aduro BioTech by 70.6% during the 2nd quarter. MetLife Investment Advisors LLC now owns 31,799 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 13,156 shares during the period. Bank of America Corp DE grew its stake in shares of Aduro BioTech by 144.8% during the 2nd quarter. Bank of America Corp DE now owns 37,141 shares of the biotechnology company’s stock valued at $260,000 after buying an additional 21,967 shares during the period. Rhumbline Advisers grew its stake in shares of Aduro BioTech by 52.2% during the 2nd quarter. Rhumbline Advisers now owns 60,733 shares of the biotechnology company’s stock valued at $425,000 after buying an additional 20,821 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of Aduro BioTech by 143.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 62,017 shares of the biotechnology company’s stock valued at $434,000 after buying an additional 36,588 shares during the period. 48.32% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:ADRO opened at $2.68 on Monday. The firm has a market cap of $212.80 million, a P/E ratio of -1.89 and a beta of 2.57. Aduro BioTech Inc has a twelve month low of $2.47 and a twelve month high of $9.93.

Aduro BioTech (NASDAQ:ADRO) last posted its earnings results on Tuesday, October 30th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.02. The business had revenue of $3.06 million for the quarter, compared to analyst estimates of $4.59 million. Aduro BioTech had a negative net margin of 591.66% and a negative return on equity of 50.03%. Research analysts forecast that Aduro BioTech Inc will post -1.18 earnings per share for the current fiscal year.

ADRO has been the subject of several research reports. BidaskClub raised shares of Aduro BioTech from a “strong sell” rating to a “sell” rating in a research note on Friday, August 31st. Oppenheimer set a $10.00 price objective on shares of Aduro BioTech and gave the company a “buy” rating in a research note on Monday, November 12th. Canaccord Genuity lowered their price objective on shares of Aduro BioTech from $30.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, November 13th. Cowen reissued a “buy” rating on shares of Aduro BioTech in a research note on Wednesday, October 31st. Finally, ValuEngine raised shares of Aduro BioTech from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 30th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. Aduro BioTech has a consensus rating of “Hold” and an average target price of $8.63.

In related news, CFO Jennifer Lew sold 5,623 shares of Aduro BioTech stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $6.50, for a total transaction of $36,549.50. Following the transaction, the chief financial officer now owns 141,813 shares in the company, valued at approximately $921,784.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Blaine Templeman sold 6,056 shares of Aduro BioTech stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $6.50, for a total transaction of $39,364.00. Following the transaction, the vice president now owns 147,437 shares in the company, valued at approximately $958,340.50. The disclosure for this sale can be found here. Insiders have sold a total of 46,927 shares of company stock worth $294,918 in the last 90 days. Company insiders own 5.00% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.dailypolitical.com/2018/12/10/aduro-biotech-inc-adro-holdings-increased-by-axa.html.

About Aduro BioTech

Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.

Featured Story: Hedge Funds

Want to see what other hedge funds are holding ADRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aduro BioTech Inc (NASDAQ:ADRO).

Institutional Ownership by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.